Member Info for Titania

Synairgen Research

Confirmation Statement Overdue on Beta Companies House website.

I hadn't seen this before today but I have no idea when it was put on their website.

Respiratory Infections

"The short- and long-term harm that respiratory infections, such as COVID-19, respiratory syncytial virus (RSV) and influenza, can inflict has never been clearer. At Janssen, we have a deep heritage of caring for those affected by respiratory infections and we’re committed to understanding these diseases so that we can both prevent infection and reduce symptoms for generations to come."

"We are working tirelessly to help those with respiratory infections, including COVID-19, RSV, and influenza, where innovative treatment and prevention approaches are urgently needed."

https://www.janssen.com/uk/our-focus/infectious-diseases-and-vaccines

Apologies if already posted.

It's dated 19/5/2023 not 13/5/2023

I've no idea if Synairgen are aware of this. I presume they are.

Can't get the link to work directly. You might have to copy and paste into your chrome browser to see it.

Https://view.connect.hhs.gov/?qs=75f11215b14d728e8d9039cb877e8a11834b2da12b7d3568b7848860c041f3856fe1bd299326b6b423a66cdefcee659236c27bfeaf610680b3f05c6514285ffc9618b0bd2a14ff734e3ed8b0d390765b

"Explore the TechWatch submission threats and areas BARDA is actively assessing."

"Coronaviruses (e.g., SARS, MERS, COVID-19)"

https://medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/

"Antiviral Treatments That the Panel Recommends Against
• The Panel recommends against the use of the following drugs for the treatment of COVID-19, except in a clinical trial:
• Interferons in nonhospitalized patients (AIIa)
• Interferon alfa or lambda in hospitalized patients (AIIa) • Nitazoxanide (BIIa)
• The Panel recommends against the use of the following drugs for the treatment of COVID-19:
• Bamlanivimab plus etesevimab, bebtelovimab, casirivimab plus imdevimab, or sotrovimab (AIII)
• Chloroquine or hydroxychloroquine and/or azithromycin in hospitalized (AI) and nonhospitalized patients (AIIa) • CCP in hospitalized patients who are immunocompetent (AI)
• Lopinavir/ritonavir and other HIV protease inhibitors in hospitalized (AI) and nonhospitalized patients (AIII)
• Systemic interferon beta in hospitalized patients (AI)"

P168
https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf

https://pubmed.ncbi.nlm.nih.gov/36451263/

Apologies if already posted.

https://www.southampton.ac.uk/research/projects/the-platform-randomised-trial-of-treatments-in-the-community-for-epidemic

Does anyone know when trading of TILS will be possible in Barclays?

Thanks in advance for a reply.

https://www.ffvcnc.org/drive

https://www.gov.uk/government/groups/the-covid-19-therapeutics-taskforce#closure-of-the-covid-19-antivirals-and-therapeutics-taskforce-on-31-march-2023

Maybe a Meta Analysis could happen or maybe not.

A Mario Castro Meta Analysis will be free.

No mention of broad spectrum antiviral!

https://www.abstractsonline.com/pp8/#!/10703/presentation/9912

Apologies if already posted.

Main Barda Drive website:-
https://drive.hhs.gov/host_tx.html